Dry Powder Inhalers (DPI)

Abstract Environmental relative humidity (RH) and temperature (T) are known to be promoters of physicochemical changes in pharmaceutical grade lactose,...

Abstract Background/Objectives: Reproducible evaluation of aerosol dispersibility remains a key challenge in the development of dry powder inhalers (DPIs), where small...

Abstract Despite being subject to a multitude of investigations, the effect of carrier particle size on the performance of adhesive...

Abstract Lower respiratory tract infections (LRTIs) constitute the fourth leading cause of mortality worldwide, resulting in over two million deaths...

Abstract Background/Objectives: This study aims to investigate the underexplored impact of capsule type on the performances of capsule-based dry powder...

Abstract Dry Powder Inhaler (DPI) formulations generally consist of drug particles with a size between 1 and 5 µm, ideal for...

Abstract Magnesium stearate (MgSt) has been used as a force control agent (FCA) to enhance the aerosol performance of carrier-based...

Abstract The development of dry powder inhalers (DPIs) for pulmonary drug delivery is complex, requiring optimization of variable factors to...

Abstract There is growing demand for simplified collection of the fine particle dose (FPD, mass of particles less than 5 µm...

Abstract Background/Objectives: The integration of machine learning (ML) and artificial intelligence (AI) has revolutionized the pharmaceutical industry by improving drug...